December 23, 2020
The end of year brings new beginnings for KI faculty startups. Lumicell’s signature imaging system has been granted fast track designation approval for breast cancer treatment. Fate Therapeutics reports positive Phase 1 data for its combination immunotherapy as well as a promising case study for its targeted NK cell therapy, both in lymphoma patients. Verastem announces Phase 2 initiation for trials in recurrent low-grade serous ovarian cancer. Syros presents positive results from Phase 2 trials in acute myeloid leukemia and an initiation plan for future trials. Finally, Dragonfly Therapeutics has licensed its first NK cell based immunotherapy candidate to Merck.